PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline. The pre-submission file is completed with French regulatory agency (ANSM) to discuss clinical trial protocol and the Phase IIa clinical trial is planned to start in 2026 once fund raising is closed with a strategic evolution of PannTheraPi’s management to drive upcoming milestones.